Real-World Experience of Using Dupilumab and Jak Inhibitors to Manage Pruritus in Epidermolysis Bullosa Pruriginosa
Epidermolysis bullosa pruriginosa (EBP) is a form of dystrophic EB associated with severe pruritus and has skewed Th2 inflammation. Our study suggests that JAK inhibitors may offer superior efficacy compared to dupilumab in treating EBP. Moreover, JAK inhibitors downregulate JAK-STAT signalling and Th1/2 cell differentiation in lesional skin while not in peripheral blood.
Authors
- Ping‐Chen Hou (ORCID: https://orcid.org/0000-0001-6021-4615)
- Wilson Aala (ORCID: https://orcid.org/0000-0003-4557-1109)
- Chao‐Kai Hsu (ORCID: https://orcid.org/0000-0003-4365-4533)
- Wei‐Ting Tu (ORCID: https://orcid.org/0000-0001-5476-5859)
- John A. McGrath (ORCID: https://orcid.org/0000-0002-3708-9964)
Institutions
- King's College London (GB)
- Institute of Dermatology (TH)
- National Cheng Kung University Hospital (TW)
- National Cheng Kung University (TW)
Publication Details
- Journal
- Skin Health and Disease
- Published
- 2024-08-19
- DOI
- https://doi.org/10.1002/ski2.445
- Citations
- 10
- Primary Topic
- Skin and Cellular Biology Research
- Type
- article
- Field-Weighted Citation Impact
- 3.26
Funders
- Ministry of Education, India
- National Cheng Kung University Hospital
- National Cheng Kung University
- National Science and Technology Council